

Grifols Egypt delivers first plasma medicines made from Egyptian plasma donations

- *Hospitals in Egypt to receive initial shipment of albumin, the start of what will be a steady stream of lifesaving therapeutics that will also include immunoglobulins and blood-clotting factors, all made from rising Egyptian plasma donations*
- *New donation centers are opening – a total of 20 will be operational by the end of 2024 – and manufacturing facilities being built as part of world's first integrated plasma-supply platform, a joint venture between Grifols and Egypt's National Service Projects Organization*
- *Grifols global leadership in creating innovative alliances between the plasma industry and the public sector is helping ensure domestic plasma strategic self-sufficiency*

Barcelona, Spain, June 7, 2023 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record of contributing to the health and well-being of people around the world, and Egypt's National Service Projects Organization (NSPO) have announced that their first plasma-derived medicines, manufactured from Egyptian donations, are available to administer to Egyptian patients.

Hospitals in Egypt will soon receive large quantities of albumin, used in major surgery and to treat trauma and severe burns. The inaugural shipment begins what will be a constant supply of essential plasma therapies that will also include immunoglobulins (Ig) for immunodeficiencies and blood-clotting factors to manage bleeding disorders.

All will be made from the increasing amounts of plasma from Egyptians, whose donations for the time being are being manufactured into medicines in Grifols' Parets del Vallès (Barcelona) plant as part of the landmark agreement that the company signed with the NSPO in November 2020.

The resulting joint venture, Grifols Egypt for Plasma Derivatives, is currently developing the world's very first integrated plasma infrastructure, including donation centers and manufacturing facilities. Of the 20 donation centers planned, six are already up and running, with another four expected to be open by the end of this year and 10 more in 2024. Construction is also underway on plasma fractionation and purification plants, plus testing and warehouse operations, in the New Administrative Capital's medical city.

Under the terms of the game-changing alliance, the Parets del Vallès plant is producing plasma medicines for export back to Egypt until construction of the new Egyptian manufacturing site is completed, expected to be at the end of 2025, and becomes operational.

“The manufacturing and delivery of plasma medicines for Egyptian patients with Egyptian plasma is a reality and a milestone in establishing an end-to-end plasma supply hub for Africa and the Middle East, said Raimon Grifols, Grifols Chief Corporate Officer.

“Today, and thanks to the generous donations of Egyptians, Egypt has taken a huge step forward in its vision to be a regional leader in plasma medicines and healthcare,” said Dr. Magdy Amin, CEO Grifols Egypt.

Through its Global Plasma Self-sufficiency Program Grifols continues to drive innovative alliances between the plasma industry and the public sector to ensure domestic plasma self-autonomy. Two years after forging its alliance with the Egyptian government, Grifols signed a pioneering long-term agreement with Canadian Blood Services, Canada’s national blood authority, to greatly increase the country’s self-sufficiency in Ig medicines through an all-Canadian supply and manufacturing infrastructure.

About Grifols Egypt for Plasma Derivatives

Grifols Egypt for Plasma Derivatives is a joint-venture company between Egypt’s National Service Projects Organization and Grifols. The strategic partnership’s combined expertise, technology and resources seeks to strengthen Egypt’s healthcare system through achieving self-sufficiency in plasma-derived medicines while reinforcing Grifols’ international expansion in the Middle East and Africa.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 400 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com

Media contacts:

Grifols

Media Press Office

media@grifols.com

Tel. +34 571 00 02

Egypt

Egypt's National Service Projects Organization

Email: nspo@nspo.com.eg

Tel: +2021816946

Investors:

Grifols Investors Relations Department

inversores@grifols.com - investors@grifols.com

Tel. +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.